GlassScriptPhysician profile
Mark J Michaud
NPI 1780621128
$2,369.69
in general payments reported to CMS, 2019-2025
27 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $484 · 2020: $63.65 · 2021: $181 · 2022: $646 · 2023: $486 · 2024: $280 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $995.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $470.17 | 2019-2025 | |
| Novo Nordisk INC | $317.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $311.25 | 2019-2023 | Repatha |
| Abbvie INC. | $278.07 | 2021-2025 | |
| Glaxosmithkline, LLC. | $152.38 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.39 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.77 | 2021-2023 | |
| Abbott Laboratories | $86.09 | 2021-2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $84.18 | 2023-2025 | Veozah |
| Merck Sharp & Dohme LLC | $73.16 | 2019-2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $66.58 | 2019-2024 | Spravato |
| Teva Pharmaceuticals USA, INC. | $43.19 | 2021-2022 | |
| Lilly USA, LLC | $38.60 | 2022-2023 | Jardiance, Emgality |
| Arbor Pharmaceuticals, INC. | $30.64 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $27.75 | 2020-2023 | Eliquis |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $25.83 | 2023 | Jornay Pm |
| Xeris Pharmaceuticals, INC. | $23.67 | 2025 | Recorlev |
| Allergan, INC. | $20.84 | 2019 | |
| Lucid Diagnostics INC. | $19.66 | 2022 | |
| Dexcom, INC. | $18.20 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $15.87 | 2019 | |
| Medtronic, INC. | $15.27 | 2024 | Minimed 780g |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.11 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.29 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.35 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.76 | 2021 | |
| Boston Scientific Corporation | $11.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Michaud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.